绿谷医药科技停产甘露特钠，相关岗位停工停产

Core Viewpoint - The company, Green Valley Pharmaceutical Technology, has announced the suspension of production for the mannitol sodium capsule product line due to the expiration of its drug registration certificate, currently awaiting approval from the drug regulatory authority [1] Group 1: Company Actions and Responses - Green Valley Pharmaceutical Technology has halted the production of mannitol sodium capsules and will close related office and production areas [1] - Employees affected by the suspension will receive wages at the minimum wage standard set by Shanghai, with social security and housing funds being paid normally [1] - The company has committed to restoring original salary standards once its operational conditions improve and it regains the ability to pay [1] Group 2: Product Background and Market Impact - Mannitol sodium capsules, developed in collaboration with Ocean University of China and the Shanghai Institute of Materia Medica, are used for mild to moderate Alzheimer's disease to improve cognitive function [1] - Since its launch in November 2019, the drug has benefited over 500,000 patients, with projected sales exceeding 2.1 million boxes in 2024 [1] - There is currently a shortage of mannitol sodium across the country, with prices on online platforms fluctuating daily [1] - The company has received over 9,300 requests from Alzheimer's patients for purchasing the drug through its hotline and online platforms [1] Group 3: Clinical Research and Development - The mechanism of action of mannitol sodium was published in a cover article in "Cell Research" in 2019, and further validation studies were published in 2024 [2] - An international Phase III clinical trial was initiated in 2020 but was abruptly halted in May 2022 due to increased dropout rates and funding issues [2] - Domestic post-marketing clinical research has involved 3,300 patients, with mid-term analysis showing 16% of patients exhibiting stable or improved efficacy indicators [3] - The final results of the post-marketing study are expected to be presented at an international academic conference in the second half of 2025 [3] Group 4: Industry Context - Alzheimer's disease remains a significant challenge in the medical field, with few new drugs approved since 2003, primarily focusing on symptom improvement [3] - Major pharmaceutical companies, including Eli Lilly, Takeda, Merck, Pfizer, and Roche, have entered the market, but no groundbreaking drugs have emerged yet [3] - The strategy for treating Alzheimer's is diversifying, with a growing number of clinical trials focusing on neuroinflammation rather than solely relying on amyloid-beta [3]